BioAtla, Inc.
BCAB
FAIR PRICE VALUATION
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
MARKET PRICE
$0.13
FAIR PRICE
$0.15
MARGIN
$0.02
P/E Ratio
N/A
Div. Yield
N/A
ROE
780.3%
Exceptional
Market Cap
$9M
Small-cap
COMING SOON
Get notified when BCAB's fair price changes
Fair Price Index app is launching soon with push notifications when valuations shift for stocks you follow.
iOS and Android · Free tier available
KEY FACTS
CEO
Jay Short
COUNTRY
US
HEADQUARTERS
San Diego
SECTOR
Healthcare
EXCHANGE
NASDAQ
METHODOLOGY
How we calculate BCAB's fair price
BioAtla, Inc.'s fair price of $0.15 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $0.13, BCAB trades 18.0% below its calculated fair value.
DCF MODEL · 50%
Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting BCAB's risk profile.
RELATIVE · 30%
Comparing BCAB's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.
ANALYST · 20%
Aggregated analyst price targets for BCAB, weighted by recency and analyst accuracy.
TRY IT YOURSELF
Want to test your own assumptions? Use our free calculators to estimate BCAB's fair value with your own inputs.
LEARN MORE
POWERED BY BULIOS
Get full analysis, financials, and AI insights for BCAB.
Explore on BuliosFAQ
What is the fair price of BCAB?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for BioAtla, Inc. is $0.15. At the current market price of $0.13, BCAB trades 18.0% below its calculated fair value.
Is BCAB overvalued or undervalued?+
BioAtla, Inc. is currently undervalued based on our valuation model. The stock trades at $0.13, which is 18.0% below the fair price of $0.15.
How often is BCAB's fair price updated?+
We update fair price calculations for BCAB daily after market close. The current fair price of $0.15 incorporates the latest market data and sector multiples.
What factors affect BCAB's fair price calculation?+
BCAB's fair price of $0.15 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of 780.3%.
Is BCAB a good buy right now?+
At $0.13, BCAB trades 18.0% below our fair value estimate of $0.15. The stock is currently undervalued. ROE stands at 780.3% (exceptional). Fair Price Index provides valuation data — always do your own research before investing.
Does BCAB pay dividends?+
BCAB does not currently pay a dividend.
RELATED STOCKS
Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.